Postdoctoral Fellowship Under A Indo-French Academia-Industry job with VELLORE INSTITUTE OF TECHNOLOGY | 192385 – Times Higher Education (THE)

Job Description

Applications are invited for a temporary Post ofPostdoctoral Fellowship under a Indo-French Academia-Industry Collaborative Projectfunded by CEFIPRA, in Centre for Bio Separation Technology, Vellore Institute of Technology (VIT).

Title of the Project:

Cost effective strategy for the induction of immune tolerance to therapeutic Factor VIII in haemophilia A

Qualification:

PhD in Biochemistry /Molecular Biology/Genetic Engineering/Biotechnology/ Microbiology/Life Sciences

Desirable (if any):

Experience in molecular cloning, expression and purification of proteins

Stipend:Rs.47,000/ per month + 10% HRASponsoring Agency:CEFIPRADuration:Upto April 2020 (3 months)

Principal Investigator:

Principal Investigator: Dr.Krishnan V (Professor & Director, Centre for BioSeparation Technology)

Coinvestigator: Prof.M.A.Vijyalakshmi (Professor, Centre for BioSeparation Technology)

Send your resume along with relevant documents pertaining to the details of qualifications, scientific accomplishments, experience (if any) and latest passport size photo etc. on or before(20/01/2020)through onlinehttp://careers.vit.ac.in

Salary:Not Disclosed by RecruiterIndustry:Education / Teaching / TrainingFunctional Area:Teaching, Education, Training, CounsellingRole:Trainee

Keyskills

immune toleranceBiochemistry/

Desired Candidate Profile

Please refer to the Job description above

Education-

Doctorate:Ph.D - Microbiology, Bio-Chemistry/Bio-Technology

Company Profile

Vellore Institute of Technology

VIT was established with the aim of providing quality higher education on par with international standards. It persistently seeks and adopts innovative methods to improve the quality of higher education on a consistent basis.The campus has a cosmopolitan atmosphere with students from all corners of the globe. Experienced and learned teachers are strongly encouraged to nurture the students. The global standards set at VIT in the field of teaching and research spur us on in our relentless pursuit of excellence. In fact, it has become a way of life for us. The highly motivated youngsters on the campus are a constant source of pride. Our Memoranda of Understanding with various international universities are our major strength. They provide for an exchange of students and faculty and encourage joint research projects for the mutual benefit of these universities. Many of our students, who pursue their research projects in foreign universities, bring high quality to their work and esteem to India and have done us proud. With steady steps, we continue our march forward. We look forward to meeting you here at VIT.

Excerpt from:
Postdoctoral Fellowship Under A Indo-French Academia-Industry job with VELLORE INSTITUTE OF TECHNOLOGY | 192385 - Times Higher Education (THE)

Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug…

SEATTLE and VANCOUVER, British Columbia, Jan. 13, 2020 /PRNewswire/ --Achieve Life Sciences, Inc. (Nasdaq: ACHV), University of Bristol, and Oracle Corporation (NYSE: ORCL) today announced the outcome of a study using Oracle's high-performance cloud infrastructure to potentially improve the speed of drug discovery and development of new treatments.

The study, "A General Mechanism for Signal Propagation in the Nicotinic Acetylcholine Receptor Family," wasled by scientists from the University of Bristol and recently published in the Journal of the American Chemical Society. It aimed to evaluate how receptors in the brain respond to nicotine. Researchers utilized new computational simulation methods to conduct 450 individual assessments of the biochemistry associated with the binding of nicotine to a subtype of nicotinic acetylcholine receptors, a key mechanism believed to be responsible for the highly-addictive nature of nicotine.

Computations that would otherwise have taken months to complete were achieved in five days using Oracle's high-performance cloud infrastructure. The speed of results represents a breakthrough in computational chemistry and is transformational from a research perspective.

"To understand why nicotine is so addictive, and to develop molecules to help people quit smoking, we need to understand how nicotine affects the nervous system," commented Professor Adrian Mulholland from Bristol's Centre for Computational Chemistry and co-author of the study. "By harnessing the power of cloud computing, we can quickly observe how nicotine exerts its effects at the molecular level. This information can inform future drug development of new treatments for companies like Achieve."

Achieve Life Sciences has partnered with the University of Bristol to formulate molecules and potential treatments to combat addiction and neurological disorders based on their lead smoking cessation compound in development, cytisinicline. Building on this research and previously conducted studies, cloud-based computer simulations can now be utilized to evaluate the effectiveness of potential new treatments more efficiently and help to accelerate the pace of discovery.

About Achieve & Cytisinicline Tobacco use is currently the leading cause of preventable death and is responsible for more than eight million deaths annually worldwide.1 It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking.2 Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development activities, the potential market size for cytisinicline, the potential benefits of cytisinicline, the ability to discover and develop new uses for cytisinicline and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Achieve ContactJason Wongjwong@bplifescience.com(415) 375-3340 ext. 4

1World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017 2Annals of Epidemiology, Volume 25, Issue 3, 179 - 182.e1

View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-university-of-bristol-and-oracle-corporation-announce-study-results-demonstrating-potential-for-accelerated-speed-of-drug-discovery-300985427.html

SOURCE Achieve Life Sciences, Inc.

Continue reading here:
Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug...

Alien bombshell: Why ‘it’s possible’ ‘invisible’ aliens are hiding somewhere on Earth – Express.co.uk

Britains first astronaut Helen Sharman recently hit the headlines after announcing impossible-to-spot aliens may already be living among us. Life as we understand it is easy to recognise: living things move, grow, eat, excrete and reproduce.

However, while life might be easy to spot, it is actually notoriously difficult to define and has had scientists and philosophers in debate for millennia.

The intelligent life we are searching for doesnt have to be humanoid

Dr Samantha Rolfe

There are more than 100 definitions of what life is.

An alternative but imperfect approach is describing life as a self-sustaining chemical system capable of Darwinian evolution, which works for many cases we want to describe.

Dr Samantha Rolfe, the astrobiology and principal technical officer at Bayfordbury Observatory, believes it is this lack of definition that presents problems when searching for life in space.

READ MORE:NASA unveils stunning photo of ISS transiting Sun

She wrote in The Conversation: Not being able to define life other than well know it when we see it means we are truly limiting ourselves to geocentric, possibly even anthropocentric, ideas of what life looks like.

When we think about aliens, we often picture a humanoid creature.

But the intelligent life we are searching for doesnt have to be humanoid.

Ms Sharman recently courted controversy after announcing aliens exist and theres no two ways about it.

DON'T MISSTESS satellite presents stunning new southern sky mosaic[VIDEO]Life discovered deep underground points to subterranean Galapagos'[INTERVIEW]Shadow land: Alien life can exist in 2D universe'[INTERVIEW]

The pioneering space explorer said: Will they be like you and me, made up of carbon and nitrogen?

Maybe not. Its possible theyre here right now and we simply cant see them.

Dr Rolf added: Such life would exist in a shadow biosphere, meaning this alien life would exhibit different biochemistry.

This alien life would consequently be outside of the realm of comprehension for humans.

Assuming it exists, such a shadow biosphere would probably be microscopic.

The Bayfordbury Observatory expert believes this alien life has not already been found due to the limited ways of studying the microscopic world.

She said: This may mean that there could indeed be many lifeforms we havent yet spotted.

We do now have the ability to sequence the DNA of unculturable strains of microbes, but this can only detect life as we know it that contain DNA.

If we find such a biosphere, however, it is unclear whether we should call it alien.

That depends on whether we mean of extraterrestrial origin or simply unfamiliar.

One popular suggestion for alternative biochemistry is one based on silicon rather than carbon.

Proponents for this position argue approximately 90 percent of the Earth is made up of silicon, iron, magnesium and oxygen, meaning there is plenty of material for building potential life.

Silicon is similar to carbon, it has four electrons available for creating bonds with other atoms.

Silicon is, however, heavier, with 14 protons compared to the six in the carbon nucleus.

While carbon can create strong double and triple bonds to form long chains useful for many functions, such as building cell walls, it is much harder for silicon.

Silicon struggles to create strong bonds, meaning long-chain molecules are far less stable.

In addition, common silicon compounds, such as silicon dioxide are generally solid at terrestrial temperatures and insoluble in water.

When compared to soluble carbon dioxide, carbon is more flexible and provides many more molecular possibilities.

Life on Earth is fundamentally different from the bulk composition of the Earth.

Another argument against a silicon-based shadow biosphere is that too much silicon is locked up in rocks.

The chemical composition of life on Earth has an approximate correlation with the chemical composition of the sun, with 98 percent of atoms in biology consisting of hydrogen, oxygen and carbon.

Therefore, if there were viable silicon lifeforms on this planet, they may have evolved elsewhere.

However, silicon-based life cannot be ruled-out, the researcher revealed.

Dr Rolfeuch wrote: Only a few years ago, scientists at Caltech managed to breed a bacterial protein that created bonds with silicon essentially bringing silicon to life.

So even though silicon is inflexible compared with carbon, it could perhaps find ways to assemble into living organisms, potentially including carbon.

And when it comes to other places in space, such as Saturns moon Titan or planets orbiting other stars, we certainly cant rule out the possibility of silicon-based life.

Go here to read the rest:
Alien bombshell: Why 'it's possible' 'invisible' aliens are hiding somewhere on Earth - Express.co.uk

The cell culture market is expected to reach USD 29.2 billion by 2024 from USD 16.0 billion in 2019, at a CAGR of 12.7% – Yahoo Finance

during the forecast period. This market is experiencing significant growth due to the growing awareness about the benefits of cell culture-based vaccines, increasing demand for monoclonal antibodies (mAbs), funding for cell-based research, growing preference for single-use technologies, growing focus on personalized medicine, and the launch of advanced cell culture products.

New York, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Culture Market by Product, Application, End User - Global Forecast to 2024" - https://www.reportlinker.com/p03665912/?utm_source=GNW On the other hand, the high cost of cell biology research and the lack of proper infrastructure for cell-based research activities are the major factors restraining the growth of this market.

Pharmaceutical and biotechnology companies are expected to dominate the market during the forecast period.Based on end user, the cell culture market is segmented into research institutes, pharmaceutical & biotechnology companies, cell banks, and hospitals & diagnostic laboratories.In 2018, pharmaceutical and biotechnology companies accounted for the largest share of the cell culture market.

The growing use of single-use technologies, increasing number of regulatory approvals for cell culture-based vaccines, and the presence of a large number of pharmaceutical players in this market are some of the factors driving the cell culture market for pharmaceutical and biotechnology companies.

Biopharmaceutical production to witness the highest growth in the cell culture market.

Based on application, the cell culture market is categorized into biopharmaceutical production, stem cell research, diagnostics, drug discovery & development, tissue engineering & regenerative medicine, and other applications.The biopharmaceutical production segment is also expected to grow at the highest CAGR during the forecast period.

The high growth of this segment is attributed to the commercial expansion of major pharmaceutical companies, growing regulatory approvals for the production of cell culture-based vaccines, and increasing demand for monoclonal antibodies (mAbs).

North America to dominate the market during the forecast period.Geographically, the cell culture market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World.In 2018, North America accounted for the largest share of the cell culture market.

The growing regulatory approvals for cell culture-based vaccines, technological advancements, growth in the biotechnology and pharmaceutical industries, higher investments in cell-based research, rising incidence of diseases such as cancer, strong government support, and conferences and symposiums that create awareness on the latest trends in cell culture technology are the key factors driving the growth of the cell culture market in North America.

The primary interviews conducted for this report can be categorized as follows: By Company Type - Tier 1: 36%, Tier 2: 45%, and Tier 3: 19% By Designation - C-level: 33%, D-level: 40%, and Others: 27% By Region - North America: 36%, Europe: 28%, Asia Pacific: 19%, Rest of the World: 17%

List of Companies Profiled in the Report Thermo Fisher Scientific (US) Merck KGaA (Germany) GE Healthcare (US) Lonza (Switzerland) Becton, Dickinson and Company (US) Corning Incorporated (US) Eppendorf AG (Germany) HiMedia Laboratories (India) Sartorius AG (Germany) PromoCell GmbH (Germany) Danaher Corporation (US) FUJIFILM Irvine Scientific (US) InvivoGen (US) CellGenix GmbH (Germany) Miltenyi Biotec (Germany)

Research Coverage:This report provides a detailed picture of the global cell culture market.It aims at estimating the size and future growth potential of the market across different segments, such as product, application, end user, and region.

The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell culture market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, and opportunities.Read the full report: https://www.reportlinker.com/p03665912/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Go here to read the rest:
The cell culture market is expected to reach USD 29.2 billion by 2024 from USD 16.0 billion in 2019, at a CAGR of 12.7% - Yahoo Finance

Casma Therapeutics Appoints Two Experts in Lysosomal Proteostasis Pathways and Functional Genomics to Scientific Advisory Board – BioSpace

Christian and Martin are at the vanguard of their respective fields, known for applying cutting edge technologies to uncover the molecular basis for physio-pathological activity, said Leon Murphy, Ph.D., chief scientific officer of Casma Therapeutics. Their expertise will greatly enrich the work of our scientific advisory board as we explore ways to leverage autophagy, the cells natural recycling process, to develop a new class of therapeutics.

Christian Grimm, a Professor of Molecular Pharmacology at the Department of Pharmacology and Toxicology, Medical Faculty, Ludwig-Maximilians-University Munich, Germany, brings world-leading expertise in the study of endo-lysosomal ion channels and their role in human disease. With a focus on electrophysiology, cell and chemical biology, Grimm has developed multiple tools and techniques to understand the role of intracellular ion channels in rare and common disorders. His extensive training from top academic institutes and experience in the pharmaceutical sector has allowed him to develop highly selective small molecule probes that modulate ion channels. He received his Ph.D. from the Free University of Berlin, Germany, followed by postdoctoral research fellowships at Harvard University and Stanford University, USA (2004-2009).

Casmas focus on developing treatments that leverage the autophagy-lysosomal system is an exciting opportunity to address several important human disorders in a whole new way, Grimm said. I look forward to working with my fellow SAB members to advise Casma on the path forward.

Martin Kampmann, an Associate Professor at the University of California, San Francisco, and a Chan Zuckerberg Biohub investigator, has pioneered the development and use of genome-wide editing approaches to study proteostasis networks in health and disease with a major focus on neurodegeneration. Kampmann has received numerous honors for his research, including the Chan Zukerberg Initiative Ben Barres Early Career Acceleration Award in 2018 and the NIH Directors New Innovator Award in 2015. He earned his Ph.D. in biological sciences from The Rockefeller University.

The autophagy-lysosomal system plays a fundamental role in preserving cellular health and is a very exciting target for neurodegeneration Kampmann said. Casma has the opportunity here to pioneer a new class of medicines based on these insights, and Im excited to be working with their team and their stellar scientific advisers.

Grimm and Kampmann will join founding scientific advisory board members Sascha Martens of the University of Vienna, Austria, and Pietro De Camilli of Yale University, both appointed in March 2019, and Steven Gygi of Harvard Medical School, who was appointed in October 2019.

About Casma Therapeutics

Casma Therapeutics is harnessing the natural cellular process of autophagy to open vast new target areas for drug discovery and development. Casma uses several approaches to intervene at strategic points throughout the autophagy-lysosome system to improve the cellular process of clearing out unwanted proteins, aggregates, organelles and invading pathogens. By boosting autophagy, Casma expects to be able to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, among other indications. Casma was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass. For more information, please visit http://www.casmatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005082/en/

More:
Casma Therapeutics Appoints Two Experts in Lysosomal Proteostasis Pathways and Functional Genomics to Scientific Advisory Board - BioSpace

Oded Rechavi Studies the RNA Nematodes Pass to Their Offspring – The Scientist

Although neurobiologist Oded Rechavi comes from a family of doctors and researchers, it was not his original plan to go into science. It wasnt something that I had thought about, he tells The Scientist. Instead, he went to Paris after high school to train as an artist and exhibited his work in his home country of Israel before enrolling at Tel Aviv University. I still didnt know exactly what Id do, whether Id be an artist or something else, he says.

At university, Rechavi became interested in studying psychology, philosophy, and biologyspecifically, the biology of the brain, which fascinated him. He earned a bachelors degree in neuroscience in 2006 and then went on to do a PhD, also at Tel Aviv. For his graduate work, he pivoted his focus to immune cells and found that when T and B cells connect with each other, they exchange macromolecules such as small interfering RNAs (siRNAs) that can break down messenger RNA molecules, preventing them from being translated into proteinsa process known as RNA interference, or RNAi (Genes Dev, 23:197179, 2009). Now we know that small RNAs are exchanged in many different organs, he says.

He has a lot of research interests and an infectious enthusiasm for things. . . . The extent of his creativity really knows no bounds.

Oliver Hobert, Columbia University

Rechavi continued to study RNA as a postdoc in Oliver Hoberts lab at Columbia University in New York. It was pretty clear when he came to visit the lab that he was really very specialincredibly thoughtful, creative, and very excited and engaged about the projects that we discussed, Hobert says. One of those projects was investigating siRNAs that C. elegans produces as a defense against viral infection. In 2011, Rechavi and colleagues demonstrated that the worms passed down those siRNAs from parent to offspring (Cell, 147:124856). Theres no virus that infects C. elegans efficiently, Rechavi explains. Only mutants that are defective in RNA [interference] are infected with viruses, and this could be in part because [nematodes] inherit siRNAs.

In 2012, Rechavi moved back to Israel and established his own lab at his alma mater. Inspired by human epidemiological studies, which have suggested that famine is associated with an increased risk of diabetes, heart disease, and obesity in subsequent generations, he wanted to see if changes in siRNAs caused by an environmental stressor could be inherited several generations down the line in nematodes. Sure enough, Rechavis group, in collaboration with Hobert, showed that starving nematodes passed down siRNAs that cause silencing of genes involved with fat regulation and stress resistance (Cell, 158:27787, 2014). We showed that small RNAs leave a mark thats perceived for multiple generations after starvation, Rechavi says. Additional studies from his group showed that inherited siRNAs can also have effects on movement and even decision making in the worms.

Hes got a great model system in C. elegans. . . . It was very impactful, and it shed a new light on these problems, says Michael Levin, a systems biologist at Tufts University who studies planarian flatworms and has written review papers with Rechavi on RNA inheritance. I always thought that his work was particularly creative and rigorous, and I think he has a very unique kind of mind.

Although Rechavi ended up focusing his career on science instead of art, he often looks for ways to combine the two. Hes a research associate in an interdisciplinary group of artists and scientists that focuses on culture, society, and philosophy at the Van Leer Jerusalem Institute. And hes also using Twitter to organize a February 2020 conference in Tel Aviv informally called The Woodstock of Biology, which will feature a collaborative art exhibition focusing on natural resources.

He has a lot of research interests and an infectious enthusiasm for things, Hobert says. The extent of his creativity really knows no bounds.

Emily Makowski is an intern atThe Scientist. Email her atemakowski@the-scientist.com.

More:
Oded Rechavi Studies the RNA Nematodes Pass to Their Offspring - The Scientist

Organ-On-A-Chip Market Increasing Demands and Sales 2018 to 2023 – BulletintheNews

The global market fororgan-on-a-chipshould grow from $11.3 billion in 2018 to $60.6 billion by 2023 at a compound annual growth rate (CAGR) of 39.9% from 2018 to 2023.

Report Scope:

The scope of this report is broad and covers various types of products available in the organ-on-a-chip market and potential application sectors in various industries. The organ-on-a-chip market is broken down by product into instruments and consumables. Revenue forecasts from 2018 to 2023 are given for each product, application, cell type and end user, with estimated valued derived from the revenues of manufacturers. Revenue generated from the installation and maintenance of instruments has been excluded from the report.

This report also includes a discussion of the major players in each regional organ-on-a-chip market. Further, it explains the major drivers and regional dynamics of the global market and current trends within the industry.The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major players in the global organ-on-a-chip market.

Get Sample Copy Of The Report:https://www.trendsmarketresearch.com/report/sample/11748

Report Includes:

56 data tables and 49 additional tables An overview of global market for organ-on-a-chip within the industry Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Description of potential applications in pharmaceutical and life science research sectors, including preclinical drugs testing, drug screening, personalized medicine, phenotypic screening, lead optimization and disease modelling Information on multi-channel 3-D microfluidic cell culture chip and discussion of their ability to imitate human micro environment in vitro Discussion on how organ on a chip is emerging as a priority testing alternative which is replacing animals in life science research, toxicology testing and drug development studies Knowledge about implementation of 3rs (replacement, refinement and reduction of animals-based research) in the industry Insights into government programs and policies in support of organ on chip and coverage of revised laws involving animal testing Company profiles of the top players in the industry, including Emulate, Hurel Corp., Insphero, Organovo and Synvivo

Summary

An organ-on-a-chip is a type of artificial organ that possesses the capability to simulate activities, mechanics and physiological response similar to that of an organ system. These are multi-channel 3-D microfluidic cell culture chips that are primarily being used in life science and drug development research because of their ability to imitate human microenvironments in vitro. The unique characteristics of organ-on-a-chip are worked out by integrating biology and advanced engineering. Cell biology, microfluidics and microfabrication are core fields paving their way towards development of organ-on-a-chip.

Request For Report Discount:https://www.trendsmarketresearch.com/report/discount/11748

Organ-on-a-chip is seen as a priority testing alternative replacing animals in life science research, toxicology testing and drug development studies around the globe. The European Union parliament is looking forward to revising laws involving animal testing. Through groups such as the European Partnership for Alternative Approaches to Animal Testing (EPAA) and International Council of Animal Protection in OECD Programmes (ICAPO), the parliament is seeking to implement policies circumventing 3R (refinement, reduction, and replacement) practices in biomedical research, according to the National Centre for the Replacement Refinement & Reduction of Animals in Research. The Federation ofAmerican Societies for Experimental Biology (FASEB), the largest coalition of biomedical research in the U.S. has made organ-on-a-chip a priority investment for research and development for next five years. Through organ-on-a-chip, FASEB is looking forward to improved productivity in research.

The global organ-on-a-chip market is projected to rise at a compound annual growth rate (CAGR) of REDACTED during the forecast period of 2018 through 2023. The market value is expected to rise from REDACTED in 2018 to REDACTED by 2023. The heart market in is projected to rise at a CAGR of REDACTED. The global heart-on-a-chip market is expected to rise from REDACTED in 2018 to over REDACTED by 2023.

Get the Buy Link:https://www.trendsmarketresearch.com/checkout/11748

See original here:
Organ-On-A-Chip Market Increasing Demands and Sales 2018 to 2023 - BulletintheNews

The science of families: Aberdeen IVF centre is at the forefront of fertility treatment – Press and Journal

If you turn right at the entrance of Aberdeen Maternity Hospital, youll inevitably come across excited visitors and proud parents cradling their new additions.

Balloons gently bob down the corridor along with bunches of flowers, and families make their way home together for the very first time.

Although a baby symbolises hope, however, the path to parenthood is not always straightforward.

Some parents give a quick glance as they pass through the doors, and look left to where their journey may have started.

For, alongside the neonatal unit where babies can receive lifesaving care, there is a department doing remarkable work.

It can be difficult for those who have yet to fall pregnant to see and hear the joy of others in such close proximity.

The lucky few, however, have experienced both sides of the building having originally turned left into Aberdeen Fertility Centre.

The unit has been at the forefront of fertility treatment for more than 30 years, with the first IVF baby born in Aberdeen in 1989.

The university department offers a clinical service to Grampian, the Highlands, Orkney and Shetland.

It is one of only four fertility centres in Scotland funded by the NHS, although patients must meet certain criteria before undergoing treatment.

Alongside investigations, the centre can offer treatment such as IVF, ICSI, egg/sperm/embryo freezing and recipient, IUI, surgical sperm retrieval and surrogacy.

The science behind these processes is mind-boggling and the clinic is also in the process of setting up a national donor bank.

For laboratory manager and embryologist Dr Liz Ferguson, helping people to fall pregnant is all in a days work.

She manages a team of 11, and can usually be found overseeing work in the lab.

According to the Human Fertilisation and Embryology Authority, IVF in particular is more popular and successful than ever before.

The reasons for fertility treatment have also gradually changed across the decades, with more same-sex couples, single women and surrogates undergoing treatment.

Liz believes that women are also putting off motherhood in a bid to climb the career ladder, and can find themselves in need of fertility treatment in their late 30s.

Increasingly these days, women want to have their career before a baby, said Liz.

Unexplained infertility is actually very common, and you have to factor in all the delays. So by the time someone has started trying to get pregnant, then, say, they wait another two years before coming to us for tests, age plays a big factor.

Fertility in women can decline quite rapidly after the age of 35.

So we always say the younger, the better because we want patients to have the best possible chance.

Liz and her team can watch life begin underneath the microscope, and work with exceptionally high-tech equipment.

We have an EmbryoScope in the lab it was funded by the Scottish Government, explained Liz. It is a special incubator where we can place the eggs once they have been fertilised.

The incubator provides a stable environment where we can watch the eggs develop, hopefully into embryos.

My job is very rewarding, but it can also be intense.

Say we have retrieved eggs from a patients, but there are only two eggs we can use.

That can be quite an anxious time, when youre injecting the sperm into the egg.

People can assume that if 10 eggs are retrieved, that means all 10 embryos will fertilise. That isnt actually the case though, as each embryo is given a score as to how viable it is.

We can also freeze embryos theyre kept in liquid nitrogen in storage tanks.

We only implant one embryo at a time, to minimise the risk of multiple pregnancies.

The team will be told two weeks after an embryo transfer as to whether a patient has fallen pregnant, but there are still many hurdles to overcome.

People are referred to us for a variety of reasons, said Liz.

We have male infertility, such as testicular damage where the patient might need surgery to retrieve the sperm.

Then theres endometriosis, which can make it difficult for the embryo to implant.

Its amazing that were able to help patients in the first place.

So when a patient comes back and sees us with their baby, theres no feeling quite like it.

I think some patients can find it quite hard to come to the fertility centre via the maternity entrance. Especially if you dont get the news you wanted, and then you see someone with a newborn baby.

We do have a side entrance, but well be completely separate from the maternity ward in the new hospital.

I feel very lucky to have this job, especially when you come across people who may have been trying to conceive for years, adds Liz.

IVF isnt a quick process, but when you finally have a baby at the end of it, thats what were all hoping for.

Thats what we work towards.

See the original post:
The science of families: Aberdeen IVF centre is at the forefront of fertility treatment - Press and Journal

What the ‘economics of violence’ tells us about Soleimani’s death | TheHill – The Hill

After Irans missile attacks on two Iraqi bases andnew sanctionsfrom President TrumpDonald John TrumpUS troops knew about attack on al-Asad airbase, were able to take shelter: report Democrats expand ground game to woo Latinos in Nevada Trump tweets message of support to Iranian protesters: 'Your courage is inspiring' MORE this week following Qassem Soleimanis death, the chorus is asking: What happens next with Iran?

The Quds Force that Soleimani led engages in unconventional warfare and intelligence collection. This means they engage in terrorism and insurgency operations outside of Irans borders.

Last weekend, the Iranian government announced that it wouldno longer abideby the terms of the 2015 nuclear deal unless the U.S. lifted sanctions. Under Iranian influence, the acting prime minister of Iraq sought to expel all5,000 U.S. troopsfrom the country. U.S. political leaders seemat oddsover how to respond.

The what happens next? refrain makes sense: Predicting human behavior in complex political environments poses a great challenge. Terrorism experts, historians, Iranian military and political experts, and Middle East scholars have issued forecasts ranging fromWorld War III to little more than ritual denunciations of the U.S.

But while individual responses aggregated up to government actions are only weakly predictable, the conditions that incentivize and constrain those responses are observable and instructive. As we saw with the deaths of al Qaeda founderOsama bin Laden, jihadist and terrorist leaderAbu Musab al-Zarqawi and ISIS leaderAbu Bakr al-Baghdadi, the death of a single individual, however powerful and justice-inducing, does not necessarily extinguish the complex movement behind that individual leader.

Wars in Iran, Iraq, Afghanistan and Syria have been about leaders of organizations competing for scarce opportunities for power and exploiting forms of identity to find leverage. We make a mistake by assigning identity labels to them. Instead, we must consider that behind every act of violence are individuals making decisions in conditions of scarcity. Violence is an economic problem not in the sense that all violent actors seek monetary gain (although some do), but in the sense that organized violence results from markets in which individuals pursue self-interests while facing constraints.

Employing the "economics of violence" perspective in asking what comes next with Iran in the aftermath of Gen. Soleimanis death, we must think in market terms. Specifically, we must employ market analysis and ask three questions:

Essentially, Soleimani was the CEO of the firm that is the Quds Force a firm that routinely engages in violence and coercion, and targets Americans and our allies. The U.S. airstrike removed the CEO; what is the impact on the firm of removing the CEO?

In most cases, even the best executives can be replaced. Sometimes, however, the leader possesses such vision and charisma that the firm suffers from the loss of the leader. The legendary Steve Jobs was replaced successfully by Tim Cook; Indra Nooyi resigned fromPepsiCo,and her successor is leading the company with a reformed vision for the future; Instagram co-founders Kevin Systrom and Mike Krieger left their company in 2018 but company revenue more thandoubledin 2019.

In the same vein, the death of bin Laden was not the death of al Qaeda and, while it is too soon to say definitively, we can expect that the death of al-Baghdadi did not spell the end of ISIS. We cannot expect that killing Soleimani will destroy Iran's Quds Force. At a minimum, the act killed a person who did bad things, and it provides some sense of justice to those affected. To understand the more strategic impact, we must look at the market.

Military victory can no longer be defined as the moment when one enemy is either killed or signs a peace treaty, because when one entrepreneur or firm exits a market, others predictably emerge. If the United States or another friendly government or institution cannot step into the void, should the Iran Revolutionary Guard Corps (IRGC) weaken, then we would be foolish to expect a change in the IRGC posture. With the strengthening of U.S. sanctions on Iran, however, the Iranian economy has suffered, likely weakening the IRGC.

A weaker IRGC could provide space for the people of Iran to organize civil institutions and gain power vis--vis oppressive ruling Supreme Leader Ali Khamenei. Does true victory mean defeating the Quds Force, or promoting a balance of political power in Iran? Removing the Quds Force's CEO cannot bring about this outcome but may contribute to such a success if conducted as part of a strategic plan.

Successful violent groups can act with agility. The successful firm adapts as market dynamics change. This means fighting like an entrepreneur. Instead of fighting only with military forces, the U.S. must compete in multiple ways. Such an approach includes attacking sources of funding and access to markets, continuing to pressure managerial capabilities and undermining IRGC abilities to recruit and retain talent.

By using these three questions, we can better understand the nature of human violence. Whatever actions Iran takes as a result of Soleimanis death, we know that the "economics of violence" perspective provides the clearest framework for understanding what happens next with Iran.

Gary M.Shiffman, Ph.D., is founder and CEO ofGiant Oakand the author ofThe Economics of Violence: How Behavioral Science Can Transform our View of Crime, Insurgency, and Terrorism(Cambridge University Press, March 2020). He teaches economic science and national security at Georgetown University.

Originally posted here:
What the 'economics of violence' tells us about Soleimani's death | TheHill - The Hill

Predictively Relevant: The Power Of Harnessing Data To Drive Better Consumer Experiences 01/13/2020 – MediaPost Communications

As we arrive at a new version of the roaring twenties, this data geek has a lot on her mind: privacy, CCPA, and the death of the cookie. Meanwhile,the average consumer is concerned with things like how do I get what I want and when I want it, for less?

In other words, for the average consumer, issues like privacy andtrust, although important, may be secondary concerns. In my experience working across brands and categories, Ive seen consumers willing to trade access and information to their data as long asthe value proposition aligns with helping them live more convenient, fulfilled, and less expensive lives.

This year at CES we witnessed the continued unveiling of devicesand services that in exchange for entre to consumers lives and data provide greater value than ever before. Some of these devices can track our movement, expression, and even thoughts.These new and updated products include:

advertisement

advertisement

Is this scary?

Not too long ago, location tracking wasperceived to be intrusive. However, it has now become second nature to pull up Google Maps and Waze to get to where you need or to provide your location data to your weather app for a more preciseforecast.

In todays world, everything can be a data source. There is an opportunity to learn more than ever before about human behavior, signals, triggers andneeds because every movement, wince, wink, smile or action can be tracked. Analysis of these signals will enable us to deliver more relevant and useful experiences that consumers not only want butalso need.And, if you overlay those data sources with machine learning and artificial intelligence (AI), which is called predictive analytics, then we can have analysis at a pace that consumersneed as technology continues to advance.

Predictive analytics enable brands to understand consumers at the individual level to deliver more relevant messages, and asan industry, we need to shift from delivering messages that we think our consumers want to hear, when they want to hear it and where to providing fulfilling experiences and true value.For example, pre-allergy season, I would love to have meds delivered to me ahead of the wheezy onslaught based on the signals I have emitted. The age of anticipatory homes means that we need to focusnot on how consumers should use products and services but why those products and services are important and add value.

So that brings us back to trust. It issomething that takes time to build but if the value exchange is right and people get the products and services that feel intuitive they will understand why they need them.

Trust from the consumer is critical. It may arrive on horseback but it will leave in a Tesla!

Read more here:
Predictively Relevant: The Power Of Harnessing Data To Drive Better Consumer Experiences 01/13/2020 - MediaPost Communications